Related Experiment Videos
Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?
Kenneth J Cohen1, Nada Jabado1, Jacques Grill1
1Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; Department of Pediatrics, McGill University, Montreal, Quebec, Canada; Université Paris-Saclay & Gustave Roussy Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique & Departement de Cancerologie de l'Enfant et de l'Adolescent, Villejuif, France.
Abstract:
Diffuse intrinsic pontine glioma (DIPG) has proven to be one of the most challenging of all pediatric cancers. Owing to a historical reticence to obtain tumor tissue for study, and based on an erroneous assumption that the biology of DIPG would mirror that of supratentorial high-grade astrocytomas, innumerable studies have been undertaken-all of which have had a negligible impact on the natural history of this disease. More recently, improvements in neurosurgical techniques have allowed for the safe upfront biopsy of DIPG, which, together with a wider use of autopsy tissue, has led to an evolving understanding of the biology of this tumor. The discovery of a recurrent somatic gain-of-function mutation leading to lysine 27 to methionine (p.Lys27Met, K27M) substitution in histone 3 variants characterizes more than 85% of DIPG, suggesting for the first time the role of the epigenome and histones in the pathogenesis of this disease, and more unified diagnostic criteria. Along with further molecular insights into the pathogenesis of DIPG, rational targets are being identified and studied in the hopes of improving the otherwise dismal outcome for children with DIPG.
Insights
Diffuse intrinsic pontine glioma (DIPG), a challenging pediatric cancer, is now better understood due to advances in tissue acquisition. A key discovery is a histone mutation found in most DIPG cases, paving the way for new treatments.
Area of Science:
- Pediatric Oncology
- Neuro-Oncology
- Cancer Genomics
Background:
- Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brain tumor with a historically poor prognosis.
- Previous research was limited by insufficient tumor tissue availability and incorrect assumptions about DIPG biology.
- Recent advancements in neurosurgery and tissue analysis have improved our understanding of DIPG.
Purpose of the Study:
- To investigate the molecular underpinnings of DIPG.
- To identify potential therapeutic targets for DIPG treatment.
- To establish more unified diagnostic criteria for DIPG.
Main Methods:
- Analysis of tumor tissue obtained through improved neurosurgical biopsy and autopsy.
- Molecular profiling to identify genetic and epigenetic alterations in DIPG.
- Comparative analysis with other high-grade astrocytomas.
Main Results:
- A recurrent histone H3 mutation (p.Lys27Met, K27M) characterizes over 85% of DIPG cases.
- This mutation highlights the role of epigenetics in DIPG pathogenesis.
- The findings suggest DIPG is a distinct molecular entity.
Conclusions:
- The identification of the K27M histone mutation provides a unifying molecular hallmark for DIPG.
- This discovery opens avenues for targeted therapies aimed at epigenetic modifications.
- Improved understanding of DIPG biology offers hope for better clinical outcomes in children.